Abstracts

Interactions Between ABT-493 Plus ABT-530 Combination and Rilpivirine or Raltegravir

ABT‐493 (protease inhibitor discovered by AbbVie and Enanta) and ABT‐530 (NS5A inhibitor) are direct acting antivirals developed as a combination regimen for treatment of chronic hepatitis C virus genotype 1‐6 infection. Rilpivirine, a non‐nucleoside reverse transcriptase inhibitor (NNRTI), and raltegravir, a HIV‐1 integrase inhibitor are often used with other antiretroviral agents in the HIV‐HCV co‐infected…

Pharmacokinetics of Dolutegravir and Rilpivirine in Combination With SMV and SOF

Anti-HCV treatment with direct-acting antivirals (DAAs)-based regimens is a priority in HIV/HCV co-infected patients (pts) with advanced liver disease. We evaluated plasma through concentration of dolutegravir and rilpivirine (DTG-RPV) used in combination with simeprevir plus sofosbuvir (SMV-SOF) in HIV/HCV co-infected pts with advanced liver disease. Pts infected with HCV and HIV-1, with advanced liver disease…

Effect of Direct Acting Antivirals on the Pharmacokinetics of Calcineurin Inhibitors

Severe hepatitis C virus (HCV) recurrence affects post-transplant survival in HCV infected patients. We describe the effect of sofosbuvir-based anti-HCV therapy on disposition of anti-calcineurin immunosuppressive drugs. Liver transplant patients (pts) with severe HCV recurrence who signed the informed consent were included in the ANRS CO23 CUPILT cohort and their characteristics recorded. Immunosuppressive therapy backbone…

Multiple-Dose Treatment With Rifabutin Reduces the Exposure of Doravirine

Doravirine is a novel, potent, HIV-1 non-nucleoside reverse transcriptase inhibitor that is primarily metabolized by oxidation via CYP3A4. A previous clinical trial demonstrated that co-administration of doravirine with multiple dose (MD) rifampin, a strong CYP3A4 inducer, resulted in decreased doravirine exposure. This study assessed the impact of MD rifabutin administration, a moderate CYP3A4 inducer, on…

Acute HIV Treatment Reverses CD8 T Cell Activation, Exhaustion, and Apoptosis

Despite viral suppression with cART, persistent inflammation contributes to pathogenesis and morbidity. We hypothesized that treatment during acute HIV infection (AHI) with an integrase inhibitor based regimen would decrease cellular activation, exhaustion, and apoptosis compared with subjects treated in chronic infection. Subjects identified in AHI (n= 18, Fiebig stages I-IV), were treated with tenofovir/emtricitabine and…

Increased Innate Function Following HIV-1 Suppression Is Linked to Epigenetic Changes

HIV-1 infection leads to both profound immune suppression and pathologic inflammation. While adaptive immune dysfunction has been extensively studied, less is known about innate immunity in the context of HIV-1. Based on the broad pathogen susceptibility in progressive HIV-1, we hypothesized that there would be aberrant innate responses. We tested innate function and investigated the…

Inhibition of P2X7 Enhances T-Cell Potential of CD34 in HIV+ c-ART Nonresponders

Although many factors are known to limit CD4 T-cell recovery during HIV infection, the impact of alteration in T-cell lymphopoiesis remains poorly understood. We hypothesize that deficient T-cell differentiation from CD34 hematopoietic progenitors (HP) could, at least partially, explain poor CD4 levels restoration under c-ART in HIV+ patients. PBMC were obtained from HIV+ immune responders…

Maraviroc and Immune Recovery in Advanced AIDS (CD4

In the CADIRIS trial 276 ART naïve patients with CD4 <100/uL were randomized to receive maraviroc (MVC) or placebo added to a standard ART regimen to evaluate the effects of CCR5 antagonism on occurrence of IRIS. No effect was demonstrable (Sierra-Madero Lancet HIV 2014). This substudy reports dynamics of phenotypic and functional cellular restoration upon…